NPP-669, a Novel Broad-Spectrum Antiviral Therapeutic with Excellent Cellular Uptake, Antiviral Potency, Oral Bioavailability, Preclinical Efficacy, and a Promising Safety Margin
Elke Lipka, Aaron M. Chadderdon, Cheryl Harteg, Matthew K. Doherty, Eric S. Simon, John M. Domagala, Dawn Reyna, Kim Hutchings, Xinmin Gan, Andrew D. White, Caroll B. Hartline, Emma A. Harden, Kathy A. Keith, Mark N. Prichard, Scott H. James, Rhonda D. Cardin, David I. Bernstein, Jacqueline F. Spencer, Ann E. Tollefson, William S.M. Wold, Károly Tóth
Abstract
for 24 h. These experiments identified a novel lead candidate, NPP-669. NPP-669 demonstrated efficacy against CMV infections in mice and AdV infections in hamsters following oral (p.o.) dosing at a dose of 1 mg/kg BID and 0.1 mg/kg QD, respectively. We further showed that NPP-669 at 30 mg/kg QD did not exhibit histological signs of toxicity in mice or hamsters. These data suggest that NPP-669 is a promising lead candidate for a broad-spectrum antiviral compound.